In vitro models have emerged demonstrating direct association between selective CLRs and SARS-CoV-2 S protein (MR; DC-SIGN; L-SIGN and MGL) mannosylated and N- and O-glycans [34,35], highlighting them as strategic therapeutic targets for the treatment of COVID-19. This evidence concerns the gene CD209 and COVID-19.